Blog
RSS FeedPosted by Michael Wonder on 24 Apr 2021
AstraZeneca’s COVID-19 vaccine: benefits and risks in context
23 April 2021 - Vaxzevria (formerly COVID-19 Vaccine AstraZeneca) is authorised in the EU to prevent COVID-19, which can cause ...
Posted by Michael Wonder on 23 Apr 2021
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from BioNTech/Pfizer and Moderns
23 April 2021 - EMA’s human medicines committee (CHMP) has adopted two important recommendations that will increase manufacturing capacity and supply ...
Posted by Michael Wonder on 22 Apr 2021
WHO and EMA to inspect Sputnik V manufacturing in May
22 April 2021 - Technical experts from the World Health Organization are due to start the next round of their ...
Posted by Michael Wonder on 21 Apr 2021
J&J resumes roll-out of COVID-19 vaccine in EU
21 April 2021 - Johnson & Johnson is planning to resume the roll-out of its COVID-19 vaccine in the EU ...
Posted by Michael Wonder on 20 Apr 2021
COVID-19 vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
20 April 2021 - EMA confirms overall benefit-risk remains positive ...
Posted by Michael Wonder on 20 Apr 2021
Pfizer and BioNTech to supply the European Union with 100 million additional doses of Comirnaty
19 April 2021 - European Union exercises option under previous agreement to order 100 million additional doses of Comirnaty, bringing total ...
Posted by Michael Wonder on 15 Apr 2021
EU drug regulator to issue view on J&J vaccine next week
15 April 2021 - Europe's drug regulator said on Wednesday it planned to issue a recommendation on Johnson & Johnson's ...
Posted by Michael Wonder on 15 Apr 2021
EMA starts review of VIR-7831 for treating patients with COVID-19
15 April 2021 - EMA is reviewing currently available data on the use of the monoclonal antibody VIR-7831 (also known as ...
Posted by Michael Wonder on 14 Apr 2021
Europe bets heavily on Pfizer in vaccine strategy overhaul
15 April 2021 - Europe has hinted it will not renew contracts for coronavirus vaccines produced by pharmaceutical giants AstraZeneca ...
Posted by Michael Wonder on 14 Apr 2021
AstraZeneca’s COVID-19 vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets
14 April 2021 - EMA continues to monitor very rare blood clots with low blood platelets that occurred after vaccination ...
Posted by Michael Wonder on 14 Apr 2021
COVID-19 vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues
14 April 2021 - As announced last week, EMA’s safety committee (PRAC) is reviewing very rare cases of unusual blood clots ...
Posted by Michael Wonder on 10 Apr 2021
Johnson & Johnson COVID-19 vaccine under review by EMA over blood clots
10 April 2021 - Europe’s drug regulator says it is reviewing rare blood clots in four people in the United States ...
Posted by Michael Wonder on 08 Apr 2021
AstraZeneca worldwide: who’s using the jab, and who’s not
9 April 2021 - A growing list of countries are either restricting or suspending the use of AstraZeneca vaccine amid it’s ...
Posted by Michael Wonder on 08 Apr 2021
With millions vaccinated, rare side-effects of jabs are emerging
7 April 2021 - Sorting signal from noise. ...
Posted by Michael Wonder on 07 Apr 2021
AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
7 April 2021 - EMA confirms overall benefit-risk remains positive. ...